colon cancer therapy (CMG Pharmaceutical)

N/A

Report date: 2025/01/26 16:41:56
NME

Base Information

Drug Namecolon cancer therapy (CMG Pharmaceutical)
Drug Alias Name2, 3-dioxygenase and Trp 2, 3-dioxygenase inhibitor (CMG pharmaceutical)CB-548
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTryptophan 2,3-dioxygenase inhibitorsIndoleamine 2,3-dioxygenase inhibitors
TargetsIndoleamine 2,3-dioxygenaseTryptophan 2,3-dioxygenase
Therapy Area/IndicationsColonic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCmg Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCmg Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsColonic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A